Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT02665143 · ClinicalTrials.gov registry record · Phase 2
A Randomized Trial of a Combination of Nintedanib/Placebo in Combination With Induction Chemotherapy for Patients With Refractory or First Relapse Acute Myeloid Leukemia
A Phase 2 study, sponsored by Yale University.
- Completed
- Registry status
- Phase 2
- Development phase
- 25
- Enrollment target
NCT02665143 is a Phase 2 study that has completed, run by Yale University. The registered enrollment target is 25 participants.
The verdict
NCT02665143, a Phase 2 study, has completed, sponsored by Yale University.
- COMPLETED
- Registry status
- Phase 2
- Development phase
- 25 participants
- Enrollment target
Study Summary
The purpose of this study is to determine if a combination of nintedanib+ induction chemotherapy can be an effective strategy for patients where outcome of relapse/refractory acute myeloid leukemia (AML) is poor.
Interventions
- DRUG Nintedanib and AML induction
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 25 participants |
| Start Date | 2016-07-21 |
| Est. Completion | 2021-03-30 |
| Phase | Phase 2 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT02665143
The ClinicalTrials.gov registry entry for NCT02665143 describes a study currently listed as completed, categorized as Phase 2. The registered enrollment target is 25 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Yale University, which has 1,492 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 1 intervention - of which Nintedanib and AML induction is the first listed.
NCT02665143 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT02665143 about?
NCT02665143 is a clinical study titled "A Randomized Trial of a Combination of Nintedanib/Placebo in Combination With Induction Chemotherapy for Patients With Refractory or First Relapse Acute Myeloid Leukemia". The purpose of this study is to determine if a combination of nintedanib+ induction chemotherapy can be an effective strategy for patients where outcome of relapse/refractory acute myeloid leukemia (AML) is poor.
What is the current status of trial NCT02665143?
This trial is currently completed. It is a Phase 2 study. The enrollment target is 25 participants. The study started on 2016-07-21. Estimated completion is 2021-03-30.
What interventions are being tested in trial NCT02665143?
The interventions under investigation include: Nintedanib and AML induction (DRUG).
Who is sponsoring clinical trial NCT02665143?
This trial is sponsored by Yale University, which has 1,492 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.